N/A
N=30,430
Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals
Neuromuscular Blockade
Bottom Line
View on ClinicalTrials.gov: NCT02914119 ↗Enrolled (actual)
30,430
Serious AEs
—
Results posted
Sep 2019
Primary outcome: Primary: Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no) — 14463; 2062 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Rocuronium (Drug); Succinylcholine (Drug); Cisatracurium (Drug); Mivacurium (Drug); Objective neuromuscular monitoring (acceleromyography) (Device); Sugammadex (Drug); Neostigmine (Drug)
- Age
- Pediatric, Adult, Older Adult · 15+ yrs
- Sex
- All
- Sponsor
- Jakob Louis Thomsen
- Primary completion
- Jun 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Non-depolarizing Neuromuscular Blocking Agent (NMBA) (Yes/no) |
14463; 2062 | — |
| PRIMARY Number of Participants With and Without Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing NMBA (Succinylcholine) (Yes/no) |
4224; 9681 | — |
| SECONDARY Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA |
0.97 | — |
| SECONDARY Number of Participants With and Without Administration of Sugammadex in Cases Receiving a Non-depolarizing NMBA (Yes/no) |
145; 12945 | — |
| SECONDARY Number of Participants With and Without Administration of Neostigmine in Cases Receiving a Non-depolarizing NMBA (Yes/no) |
8570; 7955 | — |
| SECONDARY Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively |
97 | — |
| SECONDARY Number of Participants With and Without Mild Oxygen Desaturation (<90%, But >80%) in Cases Receiving a Non-depolarizing NMBA |
1753; 14230 | — |
| SECONDARY Number of Participants With and Without Severe Oxygen Desaturation (<80%) in Cases Receiving a Non-depolarizing NMBA |
295; 15688 | — |
Summary
Aim: To explore
* the frequency of use of objective neuromuscular monitoring for assessment of depth of neuromuscular blockade in general anaesthesia
* the incidence of residual neuromuscular blockade, and
* the timing of reversal of the neuromuscular blockade at the end of anaesthesia.
We will collect data from 7 Danish anaesthesia departments, using data from the Anaesthesia Information Management System (AIMS).
Eligibility Criteria
Inclusion Criteria
Patients who received general anaesthesia with neuromuscular blockade in one of the 7 hospitals providing data for the study in the last 18 months up until the time of data collection
Data sourced from ClinicalTrials.gov (NCT02914119). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.